Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

@article{Huang2020ClinicalFO,
  title={Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China},
  author={Chaolin Huang and Ye-ming Wang and Xing-wang Li and Lili Ren and Jianping Zhao and Y. Hu and Li Zhang and Guohui Fan and Jiuyang Xu and Xiaoying Gu and Zhenshun Cheng and Ting Yu and Jia’an Xia and Yuan Wei and Wenjuan Wu and Xuelei Xie and Wen Yin and Hui Li and Min Liu and Yan Xiao and Hong Gao and Li Guo and Jungang Xie and Guangfa Wang and Rong-meng Jiang and Zhancheng Gao and Qi Jin and Jianwei Wang and Bin Cao},
  journal={Lancet (London, England)},
  year={2020},
  volume={395},
  pages={497 - 506}
}

Figures and Tables from this paper

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.

The epidemiological and clinical characteristics of novel coronavirus (2019-nCoV)-infected pneumonia in Wuhan, China, and hospital-associated transmission as the presumed mechanism of infection for affected health professionals and hospitalized patients are described.

Epidemiological and Clinical Characteristics of 17 Hospitalized Patients with 2019 Novel Coronavirus Infections Outside Wuhan, China

Data from 17 confirmed cases of novel coronavirus pneumonia infected with 2019-nCoV in Dazhou provided some information that younger age, higher lymphocytes levels and monocytes levels at the diagnoses of 2019- nCoV may contributed to faster recovery and better therapeutic outcome.

Clinical Characteristics of Patients with Severe Pneumonia Caused by the 2019 Novel Coronavirus in Wuhan, China

Clinicians should focus on advanced age, lymphocyte decline, and D-dimer elevation are important characteristics of patients with severe pneumonia to identify high-risk patients at an early stage of the disease.

Clinical Features and Treatment of 221 Patients with COVID-19 in Wuhan, China

55 severe patients with elder age and chronic comorbidities, developed more than one complication and the mortality rate was significantly higher in the severe patients compared to that in the non-severe patients, suggesting that the delayed use of corticosteroid might increase the risk of death in ICU.

Clinical features of 2019 novel coronavirus infection in Beijing.

No specific symptom was helpful in the diagnosis of 2019-nCoV infection, but relatively low WBC and lymphocyte level might be suggestive to diagnosis.

Clinical Features of Patients with Coronavirus Disease 2019 (COVID‐19) from a Designated Hospital in Beijing, China

On the basis of antiviral drugs, it is observed that antibiotics treatment, appropriate dosage of corticosteroid, and gamma globulin therapy significantly improve patients' outcomes.

MEDICAL CHARACTERISTICS OF CASES INFECTED WITH THE NOVEL CORONAVIRUS 2019 IN PUNJAB, PAKISTAN

Contamination with Covid-19 produced clusters of extreme respiratory disease, such as severe and intense coronavirus respiratory disease the new 2019-nCoV, and was linked to ICU confirmation also high death.
...

References

SHOWING 1-10 OF 43 REFERENCES

Identification of a novel coronavirus in patients with severe acute respiratory syndrome.

The novel coronavirus might have a role in causing SARS and was detected in a variety of clinical specimens from patients with SARS but not in controls.

A major outbreak of severe acute respiratory syndrome in Hong Kong.

SARS is a serious respiratory illness that led to significant morbidity and mortality in this cohort of 138 cases of suspected SARS during a hospital outbreak in Hong Kong.

A novel coronavirus associated with severe acute respiratory syndrome.

A novel coronavirus is associated with this outbreak of severe acute respiratory syndrome, and the evidence indicates that this virus has an etiologic role in SARS.

Distinct Immune Response in Two MERS-CoV-Infected Patients: Can We Go from Bench to Bedside?

It is confirmed that MERS-CoV can drive IL-17 production in humans and highlighted the critical role of IFNα in this initial stage to orchestrate a robust immune response and bring substantial arguments for the indication of early IFN α treatment during MERS -CoV infection.

Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia.

The clinical picture was remarkably similar to that of the severe acute respiratory syndrome (SARS) outbreak in 2003 and reminds us that animal coronaviruses can cause severe disease in humans.

Review of chest CT manifestations of COVID-19 infection

Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV–infected rhesus macaques

Treatment of MERS-CoV infected rhesus macaques with IFN-α2b and ribavirin reduces virus replication, moderates the host response and improves clinical outcome.